FDA COVID-19 responses and recommendations this week

By Jenni Spinner contact

- Last updated on GMT

(Hamza Jawaid/iStock via Getty Images Plus)
(Hamza Jawaid/iStock via Getty Images Plus)

Related tags: Fda, COVID-19, Coronavirus, Vaccine, Plasma

As the COVID-19 vaccines continue the early stages of circulation in the US, the agency keeps an eye on industry actions and offers advice to key players.

The first wave of US citizens are receiving COVID-19 vaccines in the country’s hospitals, clinics and, in one case, in their cars on a snowy highway​. In the meantime, the US Food and Drug Administration (FDA) is maintaining its status as a source of advice for researchers, healthcare professionals, citizens and other affected entities.

The agency has updated its FDA COVID-19 Response At-A-Glance Summary​, which provides a quick look at facts, figures, and highlights on the FDA's response efforts.

CDER conversation

The agency has posted Center for Drug Evaluation and Research (CDER) Conversation with Katie Gray, Pharm.D., acting director of CDER’s Office of Prescription Drug Promotion (OPDP)​. In the question-and-answer piece, Gray outlines the office’s COVID-19 response to date, which has centered on focused on compliance actions regarding prescription drug promotional materials making false or misleading claims about COVID-19 prevention or treatment.

Additionally, the interview touches upon the OPDP’s achievements throughout 2020, such as a multifaceted initiative intended to help support competitive markets for biological products, including biosimilars. Gray also revealed OPDP’s efforts to increase visibility and awareness with industry players, including plans to participate at the upcoming DIA Advertising and Promotion Regulatory Affairs Conference.

Plasma guidance

The FDA updated its Investigational COVID-19 Convalescent Plasma​ guidance and corresponding webpage. Revisions include updated recommendations regarding the qualification of individuals who have received an investigational COVID-19 vaccine as a participant in a clinical trial (or who have received an authorized or licensed COVID-19 vaccine)  as convalescent plasma donors.

In addition, the agency has extended the period of enforcement discretion described in the guidance. The FDA first issued an emergency use authorization (EUA)  for COVID-19 convalescent plasma for the treatment of patients hospitalized with the virus.  

Fraudulent vaccine arrest

An investigation by the FDA’s Office of Criminal Investigations has led to an arrest and filing of a criminal complaint by the US Department of Justice for introducing misbranded drugs into interstate commerce. The investigation found that defendant Johnny T. Stine, as early as March 2020, claimed to have a COVID-19 vaccine, which he offered to inject in customers for up to $1,000. His company, North Coast Biologics, had received a warning letter from the FDA ordering him to cease the promotion and sale of the unapproved, unproven vaccine product.

Unproven injectable vaccines purported to prevent or treat COVID-19, made from unknown substances under unknown conditions, present significant health risks in and of themselves​," said special agent in charge Lisa Malinowski of the FDA Office of Criminal Investigation’s Los Angeles field office. “The FDA will continue to investigate fraudulent COVID-19 treatments and bring to justice those who try to profit from the pandemic​.”

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Multiple Sclerosis Analytical Report

Multiple Sclerosis Analytical Report

PatSnap | 15-Jun-2022 | Technical / White Paper

More than 2.3 million people are living with MS worldwide. Although there is no cure, new research and innovative treatments are continuously emerging....

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Related suppliers

Follow us


View more